Number of participants with grade 3‐4 (severe or life‐threatening) treatment‐related adverse events at 1 year (raw data) · bullous pemphigoid
Doxycycline probably leads to lower number of participants with grade 3‐4 (severe or life‐threatening)… compared with prednisolone (moderate certainty).
1 finding from 1 review
Disease control: complete response at 8 weeks: excluding dropouts · bullous pemphigoid
It is very uncertain whether nicotinamide plus tetracycline changes disease control: complete response at 8 weeks: excluding dropouts compared with prednisone (very low certainty).
1 finding from 1 review
Mortality at 6 months · bullous pemphigoid
It is very uncertain whether nicotinamide plus tetracycline changes mortality at 6 months compared with prednisone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
Clobetasol propionate cream showed no clear difference in mortality at 1 year compared with oral prednisone (low certainty).
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: severe complications at day 21 · bullous pemphigoid
Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).
1 finding from 1 review
Disease control · bullous pemphigoid
Doxycycline leads to lower disease control at 6 weeks (unadjusted raw data) compared with prednisolone (high certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes clinical improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement at 4 weeks (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes histological improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes endoscopic improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
Heart rate · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…
1 finding from 1 review
Percentage of time crying · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…
1 finding from 1 review
Neonatal Infant Pain Scale (NIPS) · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…
1 finding from 1 review
Neonatal Facial Coding Score (NFCS) at 3 minutes (Supplemental breast milk versus control) · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…
1 finding from 1 review